Boston-based PureTech Health has appointed Joseph Bolen (pictured) as entrepreneur-in-residence.
He previously served as president of research and development at Moderna Therapeutics and as chief scientific officer at Millennium Pharmaceuticals.
Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough, and Bristol-Myers Squibb.
As PureTech’s entrepreneur-in-residence he will work with the firm’s company creation team to identify and pursue promising new medicines.
Also joining PureTech, which focuses on developing novel medicines, is Vincent Hennemand.
He was formerly principal in Sanofi’s corporate R&D venture group and joins the cross-disciplinary healthcare firm as its vice president of company development and operations.
Prior to that Hennemand was chief of staff to the president of global R&D and the general secretary for the corporate scientific advisory committee (SDSAC), which investigates scientific proposals and projects of potential interest to Sanofi.